Dr. Nicolette Fonseca, Ph.D.
Nicolette completed her BSc and MSc in Microbiology at Goa University (India) and her Ph.D. in Microbiology and immunology at the University of British Columbia. Her doctoral thesis investigated the regulation of the CD4+ T cell response to influenza infection. During this time, she became interested in the clinical and translational aspects of immunology research especially for the treatment of ‘cold’ tumours such as prostate cancer. She was also keen on further developing her bioinformatics skills which led to her joining the Wyatt lab team in September 2019. Her current projects seek to characterize genomic alterations in prostate cancer-derived lung metastases and to dissect the immune cell infiltrate in prostate tumours with DNA repair defects.
Dr. Edmond Kwan, M.D. Ph.D.
Edmond received his M.D. in 2009 and completed his Medical Oncology Training in Melbourne, Australia in 2017 with a strong interest in caring for patients with genitourinary cancers. He completed his Ph.D. at Monash University in July 2020 focusing on whole blood transcriptomics to identify biomarkers in advanced prostate cancer. His studies were supported by a scholarship from the National Health and Medical Research Council. During his Ph.D., he was actively involved in clinical research as a Principal Investigator and led various local and international clinical trials. In July 2021, supported by a UBC Killam Fellowship, he joined the Wyatt Lab to systemically study the genomic landscape of de novo metastatic prostate by analyzing ctDNA and tumor tissue.
Dr. Gillian Vandekerkhove, M.Sc Ph.D.
Gillian obtained her MSc from the University of Toronto in 2015 and joined the Wyatt laboratory in 2016. In 2022, she completed her Ph.D. at the University of British Columbia on the use of circulating tumour DNA in metastatic bladder cancer. She received several awards during her studies, including a three-year CIHR CGS-D scholarship. Gillian is continuing her research as a postdoctoral fellow, leveraging tissue and liquid biopsies to study the molecular landscape of aggressive bladder and prostate cancer, and relating genomic changes with clinical outcomes. She is a co-investigator on our recently awarded 2021 CIHR project grant titled “Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer”.
Dr. David Müller, M.D. Ph.D.
David graduated from medical school in Bonn, Germany in 2010. As part of his M.D. thesis, he first encountered biomarker-driven research using liquid biopsies. After splitting time between residency in urology and his Ph.D. studies on pathomechanisms of disease progression in urological malignancies, David obtained his Ph.D. at the University of Basel, Switzerland in 2021, and his board certification in urology through the Swiss Society of Urology in 2022; the same year he joined the Wyatt Lab. His research focuses on the clonal evolution of urothelial cancer under the selective pressure of anti-cancer therapy and is driven to improve clinical decision-making by implementing new biomarkers and advancing our understanding of the biological processes behind therapy resistance.
Elie completed an honours B.Sc. with distinction in molecular biology and biochemistry at Simon Fraser University in 2016. Elie has written and established a series of bioinformatics tools and pipelines to analyze circulating tumour DNA (ctDNA) in plasma from prostate and bladder cancer. His current research includes the development and application of machine learning algorithms and their translational utility in precision medicine for GU cancers. This work has so far focused on the identification and characterization of patients with specific DNA alterations that make them candidates for novel targeted treatment regimens. Elie has won multiple prestigious awards and distinctions since he began his graduate studies, including The UBC Genome Sciences and Technology Program Rotation Award ($17,334), The UBC 4 year fellowship ($92,391), The Roman M. Babicki Fellowship in Medical Research ($25,000), and the Canadian Institutes of Health Research (CIHR) Doctoral Award ($105,000).
Evan completed a B.Sc. with distinction in integrated sciences at the University of British Columbia, during which he spent a 16-month co-op tenure with the Wyatt lab (2015-2016). In 2017 he returned to pursue an M.Sc. in the Genome Science and Technology program, transferring to the Ph.D. program in 2019. Evan is a recipient of the Canada Graduate Doctoral Scholarship (CGS D) and the Michael Smith Foreign Study Supplement, the latter of which funded two months abroad conducting research at Tampere University in Finland. Evan’s research interests include the study of DNA damage repair defects in aggressive prostate cancer.
Jack holds a BSc. with distinction in biology from the University of British Columbia. Having completed a summer studentship at the Vancouver Prostate Centre in 2015, Jack decided to return for his MSc. in Genome Science and Technology in 2017. In 2019, he transferred into the Ph.D. program. Jack’s research involves interrogation of circulating tumour DNA and clonal hematopoiesis in patients with metastatic kidney cancer, via a collaboration with Drs. Nappi and Kollmannsberger at BC Cancer. He is also working with collaborators at the University Hospital in Basel, Switzerland on a non-muscle-invasive bladder cancer sequencing project. Jack holds a UBC 4-Year Doctoral Fellowship and has won various travel awards from CIHR and the UBC Genome Sciences and Technology program.
Cameron completed his BSc. in Biophysics at the University of British Columbia in 2018. In 2017 he spent 8 months in the Wyatt lab as a bioinformatics co-op student and completed an honours thesis in the lab in summer 2018. Cameron began his MSc in September 2018. The main focus of his work is to computationally identify genomic alterations in metastatic prostate cancer patients undergoing docetaxel treatment both in the castrate-sensitive and castrate-resistant setting. Cameron won a UBC Genome Sciences and Technology Program Rotation Award worth $17,333, travel awards from CIHR and the UBC Genome Sciences and Technology program, and in 2019 won a CIHR Master’s Award worth $17,500.
Matti is a senior bioinformatician at the University of Tampere. He has a wealth of experience across several different cancer types including prostate and bladder cancer. Matti was involved in some of the early characterizations of ctDNA in men with mCRPC, working closely with Dr. Wyatt. He continues to spearhead the bioinformatic aspects of several cell-free DNA sequencing projects. In particular, he is currently studying the evolution of metastatic prostate cancer genomes over time, under the selective pressures of therapy.
Andy completed his B.Sc. at UBC in a combined major between microbiology and computer science. He is currently transitioning to a Ph.D. program after originally joining the lab as a co-op student in 2019. Andy works on the bioinformatics aspects of several projects, including the characterization of evolution in de novo metastatic prostate cancer and metastatic urothelial carcinoma.
Asli finished her B.Sc. in biology at the University of British Columbia and started her graduate studies in genome sciences at the Wyatt Lab. She is interested in various aspects of prostate cancer, including using various bioinformatics methods to characterize the genomic changes during tumour progression.
Sarah is pursuing a BSc in Combined Microbiology & Immunology and Computer Science at the University of British Columbia and is currently carrying out a full-time 16-month co-op term in the Wyatt lab. She is working on inferring nucleosome positioning from prostate cancer ctDNA and is analyzing genomic data from de novo metastatic prostate cancer patients.
Wilson is pursuing a BSc in Integrated Sciences, focussing on computer science and genetics. He is a former co-op student, completing an 8-month term with the Wyatt lab. Wilson is working on analyzing the genomic profile of mCRPC patients. He continues to work part-time for the Wyatt lab.
Cecily is a laboratory research assistant who is mainly responsible for library construction and targeted sequencing of liquid and tissue biopsy samples from metastatic prostate cancer patients accrued to our province-wide collection program.
Gráinne completed her MSc in Infection, Immunity and Human Disease at the University of Leeds in 2017. Gráinne joined the Wyatt lab in Feb 2021 as a laboratory research technician and is primarily responsible for library construction and next-generation sequencing of DNA from liquid and tissue biopsy samples from prostate, bladder and kidney cancer patients.
Karan completed his BSc. in Molecular Biology and Biochemistry at Simon Fraser University in 2019 and is currently pursuing his Master of Environmental Toxicology degree (SFU). Karan’s roles as a laboratory research technician revolve primarily around blood processing and extraction of cfDNA and gDNA from liquid biopsy samples.
- Dr. Kim Chi – Vice President and Chief Medical Officer, BC Cancer
- Dr. Felix Feng – Vice Chair for Translational Research, Dept. of Radiation Oncology, UCSF
- Dr. Piet Ost – Adj Head of clinic – Radiation oncology (UZ Gent)
- Dr. Bernie Eigl – Medical Oncologist, Provincial Director – Systemic Therapy Clinical Trials, BC Cancer
- Dr. Peter Black – Associate Director, Clinical Research, Vancouver Prostate Centre
- Dr. Martin Gleave – Director, Vancouver Prostate Centre
- Dr. Himisha Beltran – Physician & Associate Professor of Medicine, Harvard Medical School
- Dr. Cyrill Rentsch – Head Clinical Research Urology of University of Basel, Basel
Emilia Chen: Former co-op research assistant (2020-2022)
Dr. Takayuki Sumiyoshi: former post-doctoral fellow (2019-2022)
Elena Schönlau: former lab manager (2019 – 2021)
Kevin Beja: former lab technician (2015 – 2020)
Amanda Wong: former co-op student (May-December 2016)
Dr. Edmund Chedgy: former urology clinical fellow (July 2015 – June 2017)
Dr. Werner Struss: former urology clinical fellow (July 2016 – June 2018)
Dr. Stephen Yip: former medical oncology fellow (July 2017 – January 2019)
Dr. Simon Fu: former medical oncology fellow (July 2018 – March 2020)